Clinical review observes undefined therapeutic roles for stereotactic ablative radiotherapy in gynecologic malignant tumors, highlighting the need to evaluate growing clinical uptake.
The role of stereotactic ablative radiotherapy (SABR) for gynecologic malignant tumors has yet to be clearly defined despite recent clinical uptake.
No takes yet. Share an insight, caveat, or question.
Donovan et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: